CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Follicular Lymphoma (previously untreated)|
|Funding Request||For the treatment of patients with previously untreated stage II bulky (>7cm), III or IV follicular lymphoma (FL)|
|Pre Noc Submission||Yes|
|NOC Date||July 5, 2018|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Hoffmann-La Roche Limited|
|Submission Date||March 15, 2018|
|Submission Deemed Complete||March 22, 2018|
|Prioritization Requested||Requested and Not Granted|
|Stakeholder Input Deadline ‡||March 29, 2018|
|Check-point meeting||May 8, 2018|
|pERC Meeting||August 16, 2018|
|Initial Recommendation Issued||August 30, 2018|
|Feedback Deadline ‡||September 14, 2018|
|pERC Reconsideration Meeting||October 18, 2018|
|Final Recommendation Issued||November 1, 2018|
|Notification to Implement Issued||November 16, 2018|
|Therapeutic Area||Follicular Lymphoma (previously untreated)|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.